VC420
/ Therabest, Boryung Group, ViGenCell
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 02, 2025
ViGenCell said Wednesday it has signed a joint development agreement with Therabest for TB-420, an iPSC-derived NK cell therapy expressing GPC3 CAR to treat hepatocellular carcinoma.
(Korea Biomedical Review)
- "Under this agreement, ViGenCell will pay Therabest a contract fee of 4 billion won ($2.8 million), along with milestone payments based on development stages. evenue will be shared according to a mutually agreed ratio upon technology transfer and upon the generation of independent sales."
Licensing / partnership • Hepatocellular Cancer
1 to 1
Of
1
Go to page
1